financetom
Business
financetom
/
Business
/
Clarus Q2 net loss widens
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Clarus Q2 net loss widens
Jul 31, 2025 2:10 PM

Overview

* Clarus ( CLAR ) Q2 sales of $55.2 mln beat analyst expectations, per LSEG data

* Net loss of $8.4 mln, adjusted net loss almost stable yr/yr

* Co completes sale of PIEPS brand for $9.1 mln

Outlook

* Clarus ( CLAR ) anticipates challenging consumer demand for the rest of the year

* Company expects benefits from structural improvements as demand normalizes

* Company sees uncertainty from tariffs impacting consumer demand

Result Drivers

* OUTDOOR SEGMENT - Sales increased by 1% due to a shift in timing for IGD revenues, partially offset by declines in direct-to-consumer channels in both North America and Europe

* ADVENTURE SEGMENT - Sales declined by 8% due to reduced demand from global OEM customers and challenges in the Australian wholesale market

* GROSS MARGIN DECLINE - Lower volumes and unfavorable product mix in the Adventure segment, particularly due to promotional sales in North America, led to a decrease in gross margin

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Beat $55.20 $53.50

mln mln (5

Analysts

)

Q2 EPS -$0.22

Q2 Net -$8.40

Income mln

Q2 Gross 35.6%

Margin

Q2 Capex $1.90

mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the recreational products peer group is "buy"

* Wall Street's median 12-month price target for Clarus Corp ( CLAR ) is $4.00, about 6.8% above its July 30 closing price of $3.73

* The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved